A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
To investigate what the body does to single doses of Sativex (i.e. the pharmacokinetics [PKs]
of four sprays containing 10.8 mg Δ9 tetrahydrocannabinol [THC] and 10 mg cannabidiol [CBD])
when mild, moderate or severe oral mucositis is induced. This will be done by looking at the
effects of the body on the drug before and after oral mucositis is induced. The study
participants will have Non-surgical Head and Neck Squamous Cell Carcinoma (HNSCC), and oral
mucositis will be induced with radiotherapy and/or chemotherapy.